Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrochlorothiazide

FDA-approved product (tablet, oral), marketed as Esidrix, Hydro-D, Hydrochlorothiazide and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrochlorothiazide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazides, plain; Thiazides, combinations with other drugs
FDA pharmacologic class
Thiazide Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrochlorothiazide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrochlorothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function

    NCT01977430 · start 2013-11

    Registered record
    Registry ID
    NCT01977430
    Conditions
    Chronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved
    Interventions
    Hydrochlorothiazide and furosemide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2013-11
    Completion
    2015-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Insufficiency; Hemodialysis Treatment; Diuresis Preserved
    InterventionHydrochlorothiazide and furosemide
    PhasePhase 4
    Registry statusUnknown

  • Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Losartana + Hydrochlorothiazide

    NCT01692717 · start 2013-02-28

    Registered record
    Registry ID
    NCT01692717
    Conditions
    Healthy Subjects
    Interventions
    Atorvastatin; Hydrochlorothiazide + Losartan; Hydrochlorothiazide + Losartan + Atorvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-02-28
    Completion
    2013-05-31
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionAtorvastatin; Hydrochlorothiazide + Losartan; Hydrochlorothiazide + Losartan + Atorvastatin
    PhasePhase 1
    Registry statusCompleted

  • Single Pill to Avert Cardiovascular Events

    NCT01313702 · start 2012-10

    Registered record
    Registry ID
    NCT01313702
    Conditions
    Cardiovascular Disease
    Interventions
    polipillV1; polipillV2; usual care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2012-10
    Completion
    2014-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionpolipillV1; polipillV2; usual care
    PhasePhase 3
    Registry statusWithdrawn

  • Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions

    NCT01713647 · start 2012-10

    Registered record
    Registry ID
    NCT01713647
    Conditions
    Fasting
    Interventions
    Amlodipin, losartan, HCTZ
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10
    Completion
    2012-12
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFasting
    InterventionAmlodipin, losartan, HCTZ
    PhasePhase 1
    Registry statusCompleted

  • Comparative Study of the Effects of Telmisartan and Nebivolol

    NCT02057328 · start 2010-12

    Registered record
    Registry ID
    NCT02057328
    Conditions
    Hypertension
    Interventions
    TELMISARTAN; NEBIVOLOL
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2010-12
    Completion
    2017-01
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTELMISARTAN; NEBIVOLOL
    PhasePhase 4
    Registry statusUnknown

  • Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.

    NCT01033071 · start 2010-01

    Registered record
    Registry ID
    NCT01033071
    Conditions
    Essential Hypertension
    Interventions
    Azilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-11
    Enrolment
    1,071

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Hypertension
    InterventionAzilsartan medoxomil and chlorthalidone; Azilsartan medoxomil and chlorthalidone; Olmesartan medoxomil and hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension

    NCT01070030 · start 2010-01

    Registered record
    Registry ID
    NCT01070030
    Conditions
    Stage II Hypertension
    Interventions
    Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-10
    Enrolment
    230

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage II Hypertension
    InterventionAliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)
    PhasePhase 4
    Registry statusCompleted

  • Survey to Assess Why People Are Not Responding to Treatment in Hypertension

    NCT01071681 · start 2009-11

    Registered record
    Registry ID
    NCT01071681
    Conditions
    Arterial Hypertension
    Interventions
    Telmisartan (Kinzal/Pritor, BAY68-9291)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-09
    Enrolment
    1,589

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArterial Hypertension
    InterventionTelmisartan (Kinzal/Pritor, BAY68-9291)
    PhaseNot recorded
    Registry statusCompleted

  • Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed)

    NCT00871871 · start 2009-03

    Registered record
    Registry ID
    NCT00871871
    Conditions
    Hypertension
    Interventions
    Hydrochlorothiazide (HCTZ); Comparator: Placebo to HCTZ; Isosorbide mononitrate (ISMN); Comparator: Placebo to ISMN
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-03
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionHydrochlorothiazide (HCTZ); Comparator: Placebo to HCTZ; Isosorbide mononitrate (ISMN); Comparator: Placebo to ISMN
    PhasePhase 1
    Registry statusCompleted

  • Polypill For Prevention of Cardiovascular Disease

    NCT00567307 · start 2009-01

    Registered record
    Registry ID
    NCT00567307
    Conditions
    Cardiovascular Disease
    Interventions
    Red Heart Pill 2b (Polypill); Standard Practice
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-01
    Completion
    2010-01
    Enrolment
    216

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Disease
    InterventionRed Heart Pill 2b (Polypill); Standard Practice
    PhasePhase 2
    Registry statusCompleted

  • Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)

    NCT00806585 · start 2008-12

    Registered record
    Registry ID
    NCT00806585
    Conditions
    Type 2 Diabetes Mellitus; Hypertension
    Interventions
    MK-0736; Comparator: Placebo; Comparator: HCTZ
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-12
    Completion
    2010-06
    Enrolment
    620

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Hypertension
    InterventionMK-0736; Comparator: Placebo; Comparator: HCTZ
    PhasePhase 2
    Registry statusTerminated

  • Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

    NCT00787605 · start 2008-11

    Registered record
    Registry ID
    NCT00787605
    Conditions
    Hypertension; Diabetes Mellitus
    Interventions
    Amlodipine; Hydrochlorothiazide (HCTZ); Aliskiren
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-11
    Completion
    2010-01
    Enrolment
    860

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension; Diabetes Mellitus
    InterventionAmlodipine; Hydrochlorothiazide (HCTZ); Aliskiren
    PhasePhase 4
    Registry statusCompleted

  • Kanagawa Combination Anti-hypertensive Therapy (K-CAT)

    NCT00492128 · start 2007-09

    Registered record
    Registry ID
    NCT00492128
    Conditions
    Hypertension
    Interventions
    Losartan/amlodipine or losartan/hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-09
    Completion
    2010-08
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionLosartan/amlodipine or losartan/hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions

    NCT01712126 · start 2007-09

    Registered record
    Registry ID
    NCT01712126
    Conditions
    Hypertension
    Interventions
    Irbesartan and Hydrochlorothiazide; Avalide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2007-09
    Completion
    2007-09
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionIrbesartan and Hydrochlorothiazide; Avalide
    PhaseNot applicable
    Registry statusCompleted

  • Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension

    NCT00441350 · start 2007-07

    Registered record
    Registry ID
    NCT00441350
    Conditions
    Hypertension
    Interventions
    OM 40; OM/HCTZ 40/12.5
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-07
    Completion
    2008-05
    Enrolment
    1,004

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionOM 40; OM/HCTZ 40/12.5
    PhasePhase 3
    Registry statusCompleted